The two most common fusion partners are the kinesin family 5B (KIF5B), identified in 70–90% of RET-positive NSCLC, and the coiled coil domain containing-6 (CCDC6), in 10–25% [193]. Here, RET is linked to non-small cell lung carcinoma.